New Paediatric Guidelines 2010

CLICK HERE for the new guidlines of the ESUR working group.

EMEA on Gadolinium contrast agents

News item 1

News item 2

(Nov. 2009)

ESUR statement

The ESUR Board strongly believes that freedom of speech by scientists is crucially important for the advancement of knowledge.

It is expected that scientists should be able to express their opinions and observations freely to their peers to stimulate discussion and debates, even on topics which might be difficult and contentious. The main objective of such endeavours is improving the quality of patients´ care and safety.

This should be conducted openly, with greatest integrity and without any external pressures. Fear of litigation by commercial organizations would damage important research and scientific debates.

We believe that controversial opinions are integral part of scientific-based discussions and are crucial for achieving high quality of patients´ care.

NSF statement

Dear colleagues,

many physicians have recently contacted the European Society of Urogenital Radiology about guidelines on gadolinium-based contrast agents and nephrogenic systemic fibrosis. After much discussion, the majority of academic members have agreed on guidelines concerning this issue, which we are pleased to release. We hope you find it helpful.

Please don’t forget to report cases to nsf(a) The European Medicines Agency has updated the SPC’s on gadolinium-based contrast agents per June 26th, 2007. The new documents, including the public assessment report as well as Q&A, can also be found on this page.

Yours sincerely,
Gertraud Heinz-Peer M.D.
ESUR Secretary/Treasurer

  1. Commission on Human Medicines on NSF (26 June 2007)
  2. Questions & Answers: NSF & Gadolinium (26 June 2007)
  3. Public Assessment Report: NSF & Gadolinium (26 June 2007)

Please note: The first three are EMEA documents and are available in all European languages at the National Medicines Agencies –> LINK.